Video

Evaluating dexamethasone intraocular suspension 9% post-cataract surgery

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|ASCRS

Cathleen McCabe, MD, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Cathleen McCabe, MD, of The Eye Associates, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Read the article highlights: Study: Dexamethasone intraocular suspension 9% offering high surgeon, patient satisfaction after cataract surgery

See more ASCRS coverage

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) AGS 2025: Long-term efficacy and safety of standalone and phaco ELT with Marc Toeteberg-Harms, MD
Related Content
ZEISS VISULAS Combi availability expands to Canada
March 24th 2025

ZEISS VISULAS Combi availability expands to Canada

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement
March 21st 2025

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Preclinical study of KIO-104 in a proliferative vitreoretinopathy model accepted for poster presentation at ARVO 2025
March 17th 2025

Preclinical study of KIO-104 in a proliferative vitreoretinopathy model accepted for poster presentation at ARVO 2025

Cyclosporine A eye drops ease ocular discomfort after cataract surgery
March 13th 2025

Cyclosporine A eye drops ease ocular discomfort after cataract surgery

© 2025 MJH Life Sciences

All rights reserved.